Who
Maged Shenouda
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Relmada Therapeutics; Chief Financial Officer, GridAI Technologies; Director, Protea Biosciences Group.
In numbers
- Trades disclosed
- 77
- Buys
- 17
- Sells
- 14
- Bought
- $3.3M
- Sold
- $1.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 14 Dec 2015
- Last trade
- 10 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $339K79,800 at $4.25 | filing |
| 10 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $339K79,800 at $4.25 | filing |
| 9 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $505K120,200 at $4.20 | filing |
| 9 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $505K120,200 at $4.20 | filing |
| 15 Dec 2025filed 16 Dec 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $48K11,665 at $4.12 | filing |
| 12 Dec 2025filed 16 Dec 2025 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —828,000 at $0.00 | filing |
| 5 Nov 2025filed 6 Nov 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.1M500,000 at $2.20 | filing |
| 26 Jun 2025filed 30 Jun 2025 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 20 May 2025filed 20 May 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K60,000 at $0.52 | filing |
| 19 May 2025filed 20 May 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K90,000 at $0.49 | filing |
| 16 May 2025filed 20 May 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $22K50,000 at $0.44 | filing |
| 11 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $71K24,120 at $2.95 | filing |
| 10 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $58K21,118 at $2.73 | filing |
| 9 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $21K8,194 at $2.55 | filing |
| 24 May 2024filed 29 May 2024 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,624 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —54,624 at $0.00 | filing |
| 31 Jan 2024filed 31 Jan 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K6,875 at $4.06 | filing |
| 30 Jan 2024filed 31 Jan 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $58K15,000 at $3.89 | filing |
| 29 Jan 2024filed 31 Jan 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $39K10,800 at $3.65 | filing |
| 15 Dec 2023filed 19 Dec 2023 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,090 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.